Simcere Pharmaceutical Group. (NYSE: SCR) reported earnings on Nov. 15. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Simcere Pharmaceutical Group. beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share contracted significantly.

Gross margins dropped, operating margins expanded, net margins shrank.

Revenue details
 Simcere Pharmaceutical Group. logged revenue of $84.6 million. The two analysts polled by S&P Capital IQ hoped for revenue of $82.3 million on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $78.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.01. The two earnings estimates compiled by S&P Capital IQ averaged $0.07 per share. GAAP EPS of $0.07 for Q3 were 30% lower than the prior-year quarter's $0.10 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 83.6%, 100 basis points worse than the prior-year quarter. Operating margin was 6.2%, 270 basis points better than the prior-year quarter. Net margin was 4.2%, 260 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $86.9 million. On the bottom line, the average EPS estimate is $0.10.

Next year's average estimate for revenue is $333.6 million. The average EPS estimate is $0.32.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 223 members out of 233 rating the stock outperform, and 10 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Simcere Pharmaceutical Group. a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group. is hold, with an average price target of $8.60.